Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Laura S. Wood"'
Autor:
Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-20 (2019)
Abstract The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune che
Externí odkaz:
https://doaj.org/article/eee5402a5743458ab14e581acfdc6861
Autor:
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Abstract Background Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown. A phase II clinical trial to investigate the feasibility of in
Externí odkaz:
https://doaj.org/article/e8cdaf92bae2439b9f7fe8654af69136
Autor:
Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. Methods A retrospective analysis o
Externí odkaz:
https://doaj.org/article/f6ec2bd029234b5785f346286c3599fb
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-12 (2017)
Abstract Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early successes and durable responses assoc
Externí odkaz:
https://doaj.org/article/36dc248e691d459ead3acefb3c33e4c9
Autor:
Michael B. Atkins, David F. McDermott, David I. Quinn, Thomas Olencki, Thomas Hutson, Brian I. Rini, Laura S. Wood, Martin H. Voss, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Allan J. Pantuck, Virginia Seery, Christopher G. Wood
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted fo
Externí odkaz:
https://doaj.org/article/e2cf889874654be18d4dbbdd7a7a921c
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these age
Externí odkaz:
https://doaj.org/article/42e72c5389024f66b21e24646a1cef7b
Autor:
Moshe C. Ornstein, Laura S. Wood
Publikováno v:
Advances in Therapy.
Autor:
David E. Gerber, Brandon A. Mahal, Abhilasha Nair, Lee Jones, Michael A. Thompson, Laura S. Wood, Nicole Richie, Anitra Fielding, Elaine Chang, Suzanne Jones, Mark D. Stewart, Alexander I. Spira
Published manuscripts supporting 23 of the 26 approvals were retrieved (as of March 2020) and the eligibility criteria specifics for each trial were extracted from each manuscript.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4a700592fa631ad5f79651118dc195
https://doi.org/10.1158/1078-0432.22484393.v1
https://doi.org/10.1158/1078-0432.22484393.v1
Autor:
David E. Gerber, Brandon A. Mahal, Abhilasha Nair, Lee Jones, Michael A. Thompson, Laura S. Wood, Nicole Richie, Anitra Fielding, Elaine Chang, Suzanne Jones, Mark D. Stewart, Alexander I. Spira
Purpose:In clinical research, eligibility criteria promote patient safety and optimize the evidence generated from clinical trials. However, overly stringent eligibility criteria, including laboratory requirements, may limit enrollment, resulting in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa6599a2e3039c77504decf3f6a61d9d
https://doi.org/10.1158/1078-0432.c.6531395.v1
https://doi.org/10.1158/1078-0432.c.6531395.v1
Autor:
Laura S. Wood, Dawn Conway, Maria Lapuente, George Salvador, Sheila Fernandez Gomez, Andrea Carroll Bullock, Geeta Devgan, Kathleen D. Burns
Publikováno v:
Journal of infusion nursing : the official publication of the Infusion Nurses Society. 45(3)
Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 1